A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7 valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 13 sites in Italy. Open to participants aged 75 Days to 105 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-02-22.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Italy.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13-valent pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine
7-valent pneumococcal conjugate vaccine
Biological: 7 valent pneumococcal conjugate vaccine
Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Achieving Predefined Antibody Levels for Concomitant Antigen Pertussis, Hepatitis B, Haemophilus Influenzae Type b, Diphtheria, Tetanus and Polio After the 2-Dose Infant Series and After the Toddler Dose
Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.
Time frame: One month after the infant series (6 months of age) and after the toddler dose (12 months of age)
Geometric Mean Antibody Concentration (GMC) of Pertussis in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)
Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose
GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.
Time frame: One month after the infant series (6 months of age) and the toddler dose (12 months of age)
Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).
Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Geometric Mean Antibody Concentration (GMC) of Diptheria and Tetanus in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).
Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Geometric Mean Antibody Concentration (GMC) of Polio Types 1, 2, and 3 in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose
GMC of Polio as measured using a polio in vitro plaque neutralization.
Time frame: one month after infant series dose 2 (6 months of age) and after the toddler dose (12 months of age)
Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Group After the 2-Dose Infant Series and Before the Toddler Dose
Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the 2-Dose Infant Series and Before Toddler Dose
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age)
Percentage of Participants Achieving an Antibody Level of ≥0.35 μg/mL in the 13vPnC Relative to the 7vPnC Group After the Toddler Dose
Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after the toddler dose (12 months of age)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Relative to 7vPnC Group After the Toddler Dose
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after toddler dose (12 months of age)
Percentage of Subjects Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose
Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).
Time frame: one month after infant series dose 2 and after the toddler dose
Geometric Mean Antibody Titer (OPA) in 13vPnC Group After the 2-Dose Infant Series and the Toddler Dose
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after infant series dose 2 and after the toddler dose
Participants were recruited in Italy from October 2006 to March 2007.
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 303 | 303 |
| Vaccinated dose 1 | 302 | 302 |
| Vaccinated dose 2 | 296 | 293 |
| Completed | 294 | 291 |
| Not completed | 9 | 12 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Failed to return | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Randomized but not consented | 1 | 0 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 294 | 291 |
| Completed | 287 | 282 |
| Not completed | 7 | 9 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 287 | 282 |
| Completed | 285 | 281 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| Percentage of Participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|
| Tenderness - Any (n=234,243,214,215,199,188) | 32.1 | 30.0 | 30.4 | 36.7 | 47.2 | 44.1 |
| Tenderness-Significant (n=224,231,199,199,164,153) | 2.7 | 3.5 | 4.5 | 5.0 | 8.5 | 5.9 |
| Swelling - Any (n=232,240,207,209,175,165) | 19.0 | 19.6 | 24.6 | 28.7 | 28.6 | 27.3 |
| Swelling - Mild (n=232,240,207,208,174,161) | 17.7 | 18.3 | 21.7 | 26.4 | 26.4 | 21.7 |
| Swelling - Moderate (n=223,229,198,195,160,157) | 3.6 | 3.1 | 5.6 | 5.1 | 7.5 | 10.2 |
| Swelling - Severe (n=222,229,197,194,159,152) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness - Any (n=233,245,213,212,178,174) | 25.8 | 26.5 | 31.5 | 34.4 | 36.5 | 36.2 |
| Redness - Mild (n=233,244,211,211,178,172) | 24.0 | 24.6 | 28.4 | 32.2 | 32.6 | 30.8 |
| Redness - Moderate (n=222,231,200,195,160,156) | 2.7 | 3.0 | 5.5 | 3.6 | 7.5 | 10.9 |
| Redness - Severe (n=243,255,197,194,159,152) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication (meds) to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
| Percentage of Participants | 13vPnC Dose 1 | 7vPnC Dose 1 | 13vPnC Dose 2 | 7vPnC Dose 2 | 13vPnC Toddler Dose | 7vPnC Toddler Dose |
|---|---|---|---|---|---|---|
| Fever ≥38°C but ≤39°C (n=247,246,227,226,204,197) | 41.7 | 38.6 | 55.5 | 60.6 | 63.7 | 52.3 |
| Fever >39°C but ≤40°C (n=224,233,204,201,167,160) | 3.6 | 4.7 | 6.9 | 7.0 | 9.6 | 12.5 |
| Fever >40°C (n=222,230,198,195,160,152) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 |
| Decreased appetite (n=246,248,220,218,198,197) | 35.4 | 34.3 | 47.3 | 45.4 | 52.0 | 57.4 |
| Irritability (n=258,259,245,243,221,227) | 72.9 | 63.7 | 75.5 | 75.3 | 74.7 | 74.9 |
| Increased sleep (n=269,276,226,232,195,196) | 65.8 | 64.5 | 57.1 | 56.5 | 53.8 | 54.6 |
| Decreased sleep (n=244,242,222,213,180,171) | 39.3 | 36.4 | 40.1 | 41.8 | 35.6 | 35.7 |
| Meds-treat symptoms (n=244,245,219,109,192,190) | 34.8 | 30.6 | 43.4 | 47.8 | 53.1 | 43.7 |
| Meds-prevent symptoms (n=230,238,208,208,172,169) | 12.6 | 18.1 | 20.2 | 24.5 | 27.9 | 24.3 |
Percentage of Participants achieving predefined antibody threshold levels for Pertussis Toxoid (PT) ≥5 ELISA units per milliliter (EU/mL), Filamentous Haemagglutinin (FHA) ≥5 or ≥7.82 EU/mL, and Pertactin (PRN) ≥5 EU/mL, ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B, Haemophilus Influenzae type b (Hib) 0.15 μg/ml, 0.01 or 0.1 IU/mL for Diphtheria, 0.1 IU/mL for Tetanus, and ≥1:8 titer for Polio (Type 1, 2, and 3) with the corresponding 95% CI for antigens are presented.
| percentage of participants | 13vPnC After 2-Dose Infant Series | 7vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Pertussis, PT ≥5 EU/mL (n=250,272,235,219) | 99.6 (97.8 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.4 to 100.0) | 100.0 (98.3 to 100.0) |
| Pertussis, FHA ≥5 EU/mL (n=243,272,229,214) | 100.0 (98.5 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.4 to 100.0) | 100.0 (98.3 to 100.0) |
| Pertussis, FHA ≥7.82 EU/mL (n=243,272,229,214) | 100.0 (98.5 to 100.0) | 100.0 (98.7 to 100.0) | 100.0 (98.4 to 100.0) | 100.0 (98.3 to 100.0) |
| Pertactin ≥5 EU/mL (n=248,270,234,217) | 100.0 (98.5 to 100.0) | 100.0 (98.6 to 100.0) | 100.0 (98.4 to 100.0) | 100.0 (98.3 to 100.0) |
| Hepatitis B ≥ 10.0 mIU/mL | 93.8 (90.2 to 96.3) | 93.1 (89.5 to 95.8) | 98.40 (96.00 to 99.60) | 98.80 (96.60 to 99.80) |
| Haemophilus Influenzae type b 0.15 μg/ml | 87.0 (82.0 to 91.1) | 90.3 (86.1 to 93.5) | 99.6 (97.7 to 100.0) | 98.2 (95.4 to 99.5) |
| Haemophilus Influenzae type b 1.0 μg/ml | 49.9 (42.7 to 56.0) | 48.7 (42.6 to 54.9) | 96.2 (92.9 to 98.2) | 92.2 (87.8 to 95.4) |
| Diptheria 0.01 IU/mL (n=207,240,164,190) | 100.0 (98.2 to 100.0) | 100.0 (98.5 to 100.0) | 100.0 (97.8 to 100.0) | 100.0 (98.1 to 100.0) |
| Diptheria 0.1 IU/mL (n=207,240,164,190) | 92.8 (88.3 to 95.9) | 96.3 (93.0 to 98.3) | 100.0 (97.8 to 100) | 100.0 (98.1 to 100.0) |
| Tetanus 0.1 IU/mL (n=155,214,125,96) | 94.2 (89.3 to 97.3) | 92.5 (88.1 to 95.7) | 97.6 (93.1 to 99.5) | 93.8 (86.9 to 97.7) |
| Polio, Type 1 ≥1:8 | 99.5 (97.3 to 100.0) | 99.6 (97.9 to 100.0) | 100.0 (97.9 to 100.0) | 100.0 (98.0 to 100.0) |
| Polio, Type 2 ≥1:8 | 95.6 (91.8 to 98.0) | 96.6 (93.6 to 98.4) | 100.0 (97.6 to 100.0) | 100.0 (97.9 to 100.0) |
| Polio, Type 3 ≥1:8 | 99.5 (97.3 to 100.0) | 98.9 (96.7 to 99.8) | 100.0 (97.6 to 100.0) | 100.0 (97.9 to 100.0) |
| Pertussis, PT (infant ≥16; Toddler ≥21) EU/mL | 95.2 (91.8 to 97.5) | 95.2 (92.0 to 97.4) | 92.8 (88.7 to 95.7) | 95.4 (91.8 to 97.8) |
| Pertussis, FHA (Infant ≥31; Toddler ≥162) EU/mL | 94.7 (91.0 to 97.1) | 95.6 (92.4 to 97.7) | 95.2 (91.6 to 97.6) | 95.3 (91.6 to 97.7) |
| Pertactin (Infant ≥40; Toddler ≥106) EU/mL | 91.9 (87.8 to 95.0) | 95.2 (91.9 to 97.4) | 94.9 (91.2 to 97.3) | 95.4 (91.7 to 97.8) |
GMC of Pertussis (PT, FHA, PRN) were measured using an anti-Bordetella pertussis enzyme-linked immunosorbent assay (ELISA). Results were recorded in ELISA units per milliliter (EU/mL)
| EU/mL | 13vPnC After 2-Dose Infant Series | 7vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Pertussis FHA | 102.87 (94.35 to 112.16) | 105.17 (97.25 to 113.73) | 463.23 (425.19 to 504.67) | 456.55 (415.06 to 502.18) |
| Pertussis PT | 50.01 (45.82 to 54.58) | 48.44 (44.71 to 52.49) | 60.89 (55.61 to 66.67) | 64.53 (59.13 to 70.42) |
| Pertussis PRN | 167.76 (149.54 to 188.18) | 166.19 (150.28 to 183.78) | 339.30 (309.16 to 372.38) | 361.70 (328.59 to 398.14) |
Percentage of subjects achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. (This is not a geometric mean comparison as suggested by the table row heading).
| % Achieving OPA Titer ≥1:8 | 13vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose |
|---|---|---|
| Common Serotypes - Serotype 4 | 100.0 (96.3 to 100.0) | 100.0 (95.8 to 100.0) |
| Common Serotypes - Serotype 6B | 90.0 (82.4 to 95.1) | 99.0 (94.3 to 100.0) |
| Common Serotypes - Serotype 9V | 100.0 (96.3 to 100.0) | 100.0 (96.1 to 100.0) |
| Common Serotypes - Serotype 14 | 100.0 (96.3 to 100.0) | 100.0 (96.2 to 100.0) |
| Common Serotypes - Serotype 18C | 97.0 (91.4 to 99.4) | 100.0 (96.3 to 100.0) |
| Common Serotypes - Serotype 19F | 96.0 (90.1 to 98.9) | 97.9 (92.7 to 99.7) |
| Common Serotypes - Serotype 23F | 97.0 (91.4 to 99.4) | 100.0 (96.3 to 100.0) |
| Additional Serotypes - Serotype 1 | 94.8 (88.3 to 98.3) | 100.0 (96.2 to 100.0) |
| Additional Serotypes - Serotype 3 | 99.0 (94.6 to 100.0) | 100.0 (96.2 to 100.0) |
| Additional Serotypes - Serotype 5 | 96.0 (90.0 to 98.9) | 100.0 (96.1 to 100.0) |
| Additional Serotypes - Serotype 6A | 95.9 (89.9 to 98.9) | 100.0 (96.2 to 100.0) |
| Additional Serotypes - Serotype 7F | 100.0 (96.4 to 100.0) | 100.0 (96.2 to 100.0) |
| Additional Serotypes - Serotype 19A | 95.6 (89.0 to 98.8) | 100.0 (96.0 to 100.0) |
Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay(OPA) for7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| Titers | 13vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose |
|---|---|---|
| Common Serotypes - Serotype 4 | 526.69 (431.88 to 642.32) | 1276.21 (1025.09 to 1588.85) |
| Common Serotypes - Serotype 6B | 191.34 (133.35 to 274.55) | 2383.31 (1850.47 to 3069.57) |
| Common Serotypes - Serotype 9V | 3585.80 (2787.34 to 4612.99) | 16384.00 (13066.97 to 20543.06) |
| Common Serotypes - Serotype 14 | 1882.96 (1446.51 to 2451.10) | 1903.89 (1580.90 to 2292.88) |
| Common Serotypes - Serotype 18C | 294.48 (221.80 to 390.98) | 1324.41 (1063.57 to 1649.22) |
| Common Serotypes - Serotype 19F | 222.86 (170.46 to 291.37) | 391.97 (296.34 to 518.46) |
| Common Serotypes - Serotype 23F | 487.51 (356.25 to 667.13) | 3679.67 (2971.61 to 4556.44) |
| Additional Serotypes - Serotype 1 | 62.63 (47.59 to 82.41) | 294.07 (226.88 to 381.15) |
| Additional Serotypes - Serotype 3 | 176.07 (144.89 to 213.96) | 504.66 (435.71 to 584.53) |
| Additional Serotypes - Serotype 5 | 127.11 (99.36 to 162.60) | 333.24 (274.24 to 404.94) |
| Additional Serotypes - Serotype 6A | 541.81 (392.09 to 748.68) | 2217.29 (1821.95 to 2698.42) |
| Additional Serotypes - Serotype 7F | 5914.33 (4710.83 to 7425.30) | 14886.35 (12560.25 to 17643.22) |
| Additional Serotypes - Serotype 19F | 157.59 (118.91 to 208.84) | 1415.08 (1140.56 to 1755.66) |
GMC of anti-hepatitis B surface antigen (HBsAg)using an Food and Drug Administration (FDA) approved in vitro diagnostic kit.
| mIU/mL | 13vPnC After 2-Dose Infant Series | 7vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Geometric Mean Antibody Concentration (GMC) for Hepatitis B in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After Toddler Dose | 260.46 (214.47 to 316.31) | 272.67 (220.83 to 336.68) | 1655.30 (1343.30 to 2039.77) | 2284.95 (1878.82 to 2778.88) |
GMC for Hib polyribosylribitol phosphate as measured by ELISA, expressed in micrograms per milliliter (μg/mL).
| μg/mL | 13vPnC After 2-Dose Infant Series | 7vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Geometric Mean Antibody Concentration (GMC) of Haemophilus Influenzae Type b (Hib) in the 13vPnC Group Relative to the 7vPnC Group After the 2-Dose Infant Series and After the Toddler Dose | 0.99 (0.80 to 1.21) | 1.00 (0.83 to 1.20) | 9.09 (7.80 to 10.60) | 8.85 (7.37 to 10.62) |
GMC of anti-diphtheria and anti-tetanus toxoids as measured by ELISA (IU/mL).
| IU/mL | 13vPnC After 2-Dose Infant Series | 7vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Diptheria (n=207,240,164,190) | 0.52 (0.46 to 0.60) | 0.67 (0.59 to 0.76) | 2.77 (2.45 to 3.13) | 3.71 (3.28 to 4.20) |
| Tetanus (n=155,214,125,96) | 0.53 (0.45 to 0.63) | 0.63 (0.53 to 0.74) | 2.62 (2.12 to 3.25) | 2.09 (1.56 to 2.81) |
GMC of Polio as measured using a polio in vitro plaque neutralization.
| Titers | 13vPnC After 2-Dose Infant Series | 7vPnC After 2-Dose Infant Series | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|---|---|
| Polio Type 1 (n=207,262,156,179) | 180.72 (154.31 to 211.64) | 207.17 (178.64 to 240.25) | 924.52 (782.71 to 1092.03) | 1348.04 (1163.56 to 1561.77) |
| Polio Type 2 (n=205,262,153,175) | 123.74 (102.68 to 149.13) | 130.39 (109.96 to 154.63) | 1141.62 (958.68 to 1359.47) | 1340.51 (1147.88 to 1565.48) |
| Polio Type 3 (n=205,262,153,178) | 397.32 (327.00 to 482.76) | 452.14 (382.57 to 534.35) | 1567.64 (1289.72 to 1905.45) | 2421.31 (2072.82 to 2828.39) |
Percentages of Participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC After 2-Dose Infant Series | 13vPnC Before Toddler Dose |
|---|---|---|
| Common Serotypes - Serotype 4 | 96.6 (93.6 to 98.4) | 66.9 (60.6 to 72.9) |
| Common Serotypes - Serotype 6B | 58.4 (52.2 to 64.4) | 76.3 (70.3 to 81.6) |
| Common Serotypes - Serotype 9V | 94.7 (91.2 to 97.1) | 70.5 (64.2 to 76.2) |
| Common Serotypes - Serotype 14 | 94.2 (90.6 to 96.7) | 94.4 (90.6 to 97.0) |
| Common Serotypes - Serotype 18C | 92.4 (88.5 to 95.3) | 53.0 (46.4 to 59.5) |
| Common Serotypes - Serotype 19F | 95.1 (91.7 to 97.3) | 92.4 (88.2 to 95.4) |
| Common Serotypes - Serotype 23F | 68.6 (62.6 to 74.1) | 32.3 (26.4 to 38.7) |
| Additional Serotypes - Serotype 1 | 96.6 (93.6 to 98.4) | 83.4 (78.0 to 87.9) |
| Additional Serotypes - Serotype 3 | 92.8 (89.0 to 95.6) | 30.8 (24.9 to 37.1) |
| Additional Serotypes - Serotype 5 | 91.6 (87.5 to 94.6) | 87.3 (82.4 to 91.3) |
| Additional Serotypes - Serotype 6A | 86.5 (81.8 to 90.4) | 86.4 (81.4 to 90.5) |
| Additional Serotypes - Serotype 7F | 98.5 (96.2 to 99.6) | 90.7 (86.3 to 94.1) |
| Additional Serotypes - Serotype 19A | 98.5 (96.1 to 99.6) | 96.2 (92.9 to 98.2) |
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC After 2-Dose Infant Series | 13vPnC Before Toddler Dose |
|---|---|---|
| Common Serotypes - Serotype 4 | 2.38 (2.11 to 2.67) | 0.53 (0.48 to 0.59) |
| Common Serotypes - Serotype 6B | 0.41 (0.36 to 0.47) | 0.61 (0.54 to 0.69) |
| Common Serotypes - Serotype 9V | 1.68 (1.51 to 1.86) | 0.48 (0.43 to 0.52) |
| Common Serotypes - Serotype 14 | 2.84 (2.44 to 3.31) | 2.03 (1.79 to 2.30) |
| Common Serotypes - Serotype 18C | 1.72 (1.54 to 1.93) | 0.35 (0.32 to 0.39) |
| Common Serotypes - Serotype 19F | 3.42 (2.95 to 3.97) | 0.94 (0.83 to 1.06) |
| Common Serotypes - Serotype 23F | 0.61 (0.53 to 0.71) | 0.26 (0.23 to 0.29) |
| Additional Serotypes - Serotype 1 | 2.30 (2.03 to 2.60) | 0.68 (0.61 to 0.75) |
| Additional Serotypes - Serotype 3 | 1.15 (1.04 to 1.28) | 0.25 (0.22 to 0.27) |
| Additional Serotypes - Serotype 5 | 1.27 (1.14 to 1.41) | 0.88 (0.80 to 0.97) |
| Additional Serotypes - Serotype 6A | 1.17 (1.02 to 1.33) | 0.81 (0.72 to 0.92) |
| Additional Serotypes - Serotype 7F | 2.06 (1.88 to 2.26) | 0.76 (0.70 to 0.82) |
| Additional Serotypes - Serotype 19F | 2.87 (2.55 to 3.24) | 1.20 (1.06 to 1.35) |
Percentages of Participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|
| Common Serotypes - Serotype 4 (n=244,245) | 100.0 (98.5 to 100.0) | 100.0 (98.5 to 100.0) |
| Common Serotypes - Serotype 6B (n=243,243) | 100.0 (98.5 to 100.0) | 100.0 (98.5 to 100.0) |
| Common Serotypes - Serotype 9V (n=235,248) | 100.0 (98.4 to 100.0) | 100.0 (98.5 to 100.0) |
| Common Serotypes - Serotype 14 (n=237,240) | 99.6 (97.7 to 100.0) | 99.6 (97.7 to 100.0) |
| Common Serotypes - Serotype 18C (n=245,245) | 99.2 (97.1 to 99.9) | 99.6 (97.8 to 100.0) |
| Common Serotypes - Serotype 19F (n=243,245) | 98.8 (96.4 to 99.7) | 98.4 (95.9 to 99.6) |
| Common Serotypes - Serotype 23F (n=240,243) | 99.2 (97.0 to 99.9) | 98.8 (96.4 to 99.7) |
| Additional Serotypes - Serotype 1 (n=244,240) | 99.6 (97.7 to 100.0) | 3.3 (1.4 to 6.5) |
| Additional Serotypes - Serotype 3 (n=245,218) | 93.9 (90.1 to 96.5) | 6.7 (3.9 to 10.6) |
| Additional Serotypes - Serotype 5 (n=245,243) | 100.0 (98.5 to 100.0) | 70.2 (63.6 to 76.2) |
| Additional Serotypes - Serotype 6A (n=243,243) | 99.6 (97.7 to 100.0) | 86.4 (81.5 to 90.5) |
| Additional Serotypes - Serotype 7F (n=242,243) | 99.6 (97.7 to 100.0) | 4.9 (2.6 to 8.5) |
| Additional Serotypes - Serotype 19A (n=241,241) | 100.0 (98.5 to 100.0) | 99.6 (97.7 to 100.0) |
Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC After Toddler Dose | 7vPnC After Toddler Dose |
|---|---|---|
| Common Serotypes - Serotype 4 (n=244,245) | 4.77 (4.29 to 5.30) | 7.08 (6.41 to 7.83) |
| Common Serotypes - Serotype 6B (n=243,243) | 10.00 (8.79 to 11.38) | 10.39 (9.14 to 11.82) |
| Common Serotypes - Serotype 9V (n=235,248) | 3.02 (2.74 to 3.32) | 4.10 (3.72 to 4.51) |
| Common Serotypes - Serotype 14 (n=237,240) | 10.30 (9.26 to 11.47) | 11.99 (10.77 to 13.35) |
| Common Serotypes - Serotype 18C (n=245,247) | 2.83 (2.55 to 3.14) | 4.26 (3.85 to 4.70) |
| Common Serotypes - Serotype 19F (n=243,245) | 9.01 (7.84 to 10.36) | 8.06 (7.06 to 9.21) |
| Common Serotypes - Serotype 23F (n=244,245) | 3.43 (3.02 to 3.88) | 4.87 (4.30 to 5.51) |
| Additional Serotypes - Serotype 1 (n=244,240) | 5.76 (5.12 to 6.47) | 0.03 (0.03 to 0.04) |
| Additional Serotypes - Serotype 3 (n=245,240) | 1.22 (1.09 to 1.35) | 0.07 (0.06 to 0.08) |
| Additional Serotypes - Serotype 5 (n=245,218) | 3.59 (3.25 to 3.96) | 0.56 (0.49 to 0.64) |
| Additional Serotypes - Serotype 6A (n=243,243) | 6.78 (6.04 to 7.61) | 1.42 (1.21 to 1.66) |
| Additional Serotypes - Serotype 7F (n=242,243) | 4.31 (3.94 to 4.72) | 0.04 (0.04 to 0.05) |
| Additional Serotypes - Serotype 19F (n=241,241) | 9.81 (8.82 to 10.92) | 4.24 (3.85 to 4.67) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 6/303 (2%) | 188/303 (62%) |
| 7vPnC Infant Series | — | 10/303 (3.3%) | 183/303 (60.4%) |
| 13vPnC Post-Infant Series | — | 8/294 (2.7%) | 96/294 (32.7%) |
| 7vPnC Post-Infant Series | — | 11/291 (3.8%) | 90/291 (30.9%) |
| 13vPnC Toddler Series | — | 3/287 (1%) | 165/287 (57.5%) |
| 7vPnC Toddler Series | — | 1/282 (0.4%) | 170/282 (60.3%) |
| 13vPnC 6-Month Follow-up | — | 9/290 (3.1%) | 1/290 (0.3%) |
| 7vPnC 6-Month Follow-up | — | 11/288 (3.8%) | 0/288 (0%) |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/303 | 1/303 | 3/294 | 2/291 | 0/287 | 0/282 | 0/290 | 4/288 |
| BronchiolitisInfections and infestations | 2/303 | 3/303 | 0/294 | 0/291 | 0/287 | 0/282 | 1/290 | 0/288 |
| VomitingGastrointestinal disorders | 0/303 | 0/303 | 1/294 | 0/291 | 2/287 | 0/282 | 1/290 | 0/288 |
| Febrile convulsionNervous system disorders | 0/303 | 0/303 | 2/294 | 0/291 | 1/287 | 0/282 | 2/290 | 1/288 |
| BronchopneumoniaInfections and infestations | 0/303 | 0/303 | 0/294 | 2/291 | 0/287 | 0/282 | 0/290 | 0/288 |
| DiarrhoeaGastrointestinal disorders | 0/303 | 0/303 | 0/294 | 0/291 | 1/287 | 1/282 | 0/290 | 0/288 |
| PyrexiaGeneral disorders | 0/303 | 0/303 | 0/294 | 1/291 | 0/287 | 1/282 | 0/290 | 0/288 |
| Gastroenteritis adenovirusInfections and infestations | 0/303 | 0/303 | 0/294 | 0/291 | 1/287 | 0/282 | 0/290 | 0/288 |
| Gastroenteritis rotavirusInfections and infestations | 0/303 | 1/303 | 0/294 | 0/291 | 1/287 | 0/282 | 0/290 | 1/288 |
| PharyngitisInfections and infestations | 0/303 | 1/303 | 0/294 | 0/291 | 1/287 | 0/282 | 0/290 | 1/288 |
| Event | 13vPnC Infant Series | 7vPnC Infant Series | 13vPnC Post-Infant Series | 7vPnC Post-Infant Series | 13vPnC Toddler Series | 7vPnC Toddler Series | 13vPnC 6-Month Follow-up | 7vPnC 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/303 | 12/303 | 2/294 | 5/5 | 8/287 | 3/282 | 0/290 | 0/288 |
| UrticariaSkin and subcutaneous tissue disorders | 0/303 | 0/303 | 0/294 | 2/291 | 1/1 | 0/282 | 0/290 | 0/288 |
| IrritabilityGeneral disorders | 185/245 | 183/243 | — | — | — | — | — | — |
| IrritabilityGeneral disorders | 188/258 | 165/259 | — | — | 165/221 | 170/227 | — | — |
| Increased sleepGeneral disorders | 177/269 | 178/276 | — | — | 105/195 | 107/196 | — | — |
| Fever ≥38°C but ≤39°CGeneral disorders | 103/247 | 95/246 | — | — | 130/204 | 103/197 | — | — |
| Fever ≥38°C but ≤39°CGeneral disorders | 126/227 | 137/226 | — | — | — | — | — | — |
| Decreased appetiteGeneral disorders | 87/246 | 85/248 | — | — | 103/198 | 113/197 | — | — |
| Increased sleepGeneral disorders | 129/226 | 131/232 | — | — | — | — | — | — |
| Decreased appetiteGeneral disorders | 104/220 | 99/218 | — | — | — | — | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.9 ± 0.3 | 2.9 ± 0.3 | 2.9 ± 0.3 |
| Gender(participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 138 | 133 | 271 |
| Male | 164 | 170 | 334 |
The record gives a start of Oct 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 4 years 7 months after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →